Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Microplaque Trial to Assess the Safety and Efficacy of XCUR17 Topical Gel Compared to a Vehicle Gel and a Positive Comparator (Daivonex Cream) in Patients with Mild to Moderate Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Microplaque Trial to Assess the Safety and Efficacy of XCUR17 Topical Gel Compared to a Vehicle Gel and a Positive Comparator (Daivonex Cream) in Patients with Mild to Moderate Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calcipotriol (Primary) ; XCUR 17 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Therapeutic Use
  • Sponsors Exicure

    • Most Recent Events

    • 17 Oct 2019 According to an Exicure media release, Dr. David Giljohann, presented results at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Munich.
    • 16 Oct 2019 Results published in Exicure Media Release
    • 14 Oct 2019 According to an Exicure media release, Dr. David Giljohann, PhD (CEO) will present clinical data from this study at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (Munich, 16th Oct 2019).Dr. Giljohanns presentation will present new biomarker and histology data derived from the study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top